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Abstract: Objective: To investigate whether age-related macular degeneration (AMD) is associated with the development 
of ischemic and hemorrhagic stroke among elderly Americans 
Design: Population-based cohort study. 
Participants: The five percent random sample of 2000-2003 Medicare enrollees was obtained. The cohort (n=1,519,086) 
consisted of enrollees who were aged 65 or older at the first two-year (January 1, 2000 to December 31, 2001). 
Methods: Baseline demographic variables and chronic conditions (AMD and type, history of myocardial infarction (MI), 
stroke, hypertension, and diabetes) were defined based on the occurrence of relevant ICD-9 codes in relevant diagnosis 
fields of the baseline Medicare Data. We excluded 215,900 persons who had a diagnosis of MI or stroke during baseline 
period to form a cohort of 1,303,186 individuals who were free of major cardio-cerebral vascular disease (CVD) at base-
line. 
Main Outcome Measures: In two years of follow-up (January 1, 2002 to December 31, 2003), a total of 89,501 incident 
stroke cases were identified, including 80,018 ischemic, 7048 hemorrhagic, and 2,435 stroke cases of both types. 
Results: Baseline mean age was 75 years (Standard Divination=7.7), with 60% women and 88% whites. The prevalence of 
AMD was 10.6%, with 19.7% being neovascular AMD and 80.3% being non-neovascular AMD. Baseline age, gender, 
race, hypertension, and diabetes adjusted 2-year incident odds ratios and 95% confidence internal of stroke associated 
with AMD were 1.31 (1.26, 1.36) for neovascular AMD, 1.18 (1.15, 1.21) for non-neovascular AMD, and 1.21 (1.18, 
1.23) for either neovascular or non-neovascular AMD. 
Conclusion: The findings are suggestive of an association between AMD, especially neovascular AMD, and incident 
stroke, independent of demographic factors and co-morbidity. These findings, if confirmed by other studies that control 
for smoking and other lifestyle covariables not measured in this study, suggest the possibility of shared common antece-
dents between stroke and AMD. 
Keywords: Age-related macular degeneration, stroke, Medicare medical claims, follow-up study. 
  Age-related macular degeneration (AMD) is the leading 
cause of severe vision loss among elderly persons. However, 
the etiology of AMD is poorly understood. Genetic factors 
[1-3], smoking [4,5], and less consistently oxidative stress, 
long-term exposure to sunlight, or low levels of antioxidants 
[6,7], nutritional factors [8], obesity [9,10], and lipid levels 
[11,12] have been implicated as possible risk factors for the 
development of AMD. Many of these factors are also tradi-
tional risk factors for cardiovascular and cerebral vascular 
diseases, the leading cause of death and disability in the   
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United States and other developed countries. The objective 
of this study is to investigate whether AMD, especially 
neovascular AMD, is related to the occurrence of incident 
stroke among elderly Americans. 
POPULATION AND METHODS 
Study Population 
  A 5% random sample of Medicare beneficiaries’ data and 
their medical reimbursement claims data were obtained from 
the Center for Medicare and Medicaid Services (CMS) after 
the CMS Privacy Board review and approval of the data re-
quest. We included all enrollees from this random sample dur-
ing the first two years (January 1, 2000 to December 31, 2001) 
to form a cohort of persons aged >65 years (n=1,519,086), 
after excluding persons enrolled in Medicare before 65 years 
of age and persons with conflicting demographic information 
(date of birth, race, or gender) in the CMS demographic data-
bases from different years. The research identifiable Carrier 38    The Open Ophthalmology Journal, 2008, Volume 2  Liao et al. 
files, inpatient and outpatient files, and enrollment demo-
graphic files for the entire study period (2000-2003) were ob-
tained from CMS and used for this study. 
Definitions of Key Variables 
  Baseline demographic variables and chronic conditions 
(AMD, history of myocardial infarction (MI), stroke, hyper-
tension, and diabetes) were extracted from the Medicare 
Claims database during the 2-year baseline period, based on 
any occurrence of relevant ICD-9 codes in either the “Claim 
Diagnosis Code” or the “Line Diagnosis Code” field of the 
Medicare claim form. The definitions and their correspond-
ing ICD-9 codes of AMD, MI, stroke, hypertension, and 
diabetes are summarized in Table 1 . The following algo-
rithms and the ICD-9 codes were used to define stroke [13]: 
a.  Any occurrence of 430, 431, 432.0-432.9, 433.01, 
433.21, 433.31, 433.81 or 433.91, 434.00-434.91, or 
436, on Medicare claim’s Diagnosis Code fields; or 
b.  Any co-occurrences of V57 together with 342.00-
342.92, 430, 431, 432.0-432.9, 433.00-433.91, 434.00-
434.91, 435.0-435.9, 436, 437.0-437.9, 438.0-438.9, or 
438.10-438.89 on Medicare claims’ diagnosis code 
fields; or 
c.  Any co-occurrences of 433.00-433.91 or 435.0-435.9 
together with 342.00-342.92, 430, 431, 432.0-432.9, 
434.00-434.91, or 436 on Medicare claims’ diagnosis 
code fields. 
  A person was identified as having history of stroke if 
he/she met any of the above criteria during the baseline pe-
riod. A person was identified as having a history of MI if 
there was any occurrence of ICD-9 codes 410.00 - 410.92. 
To derive a baseline cardio-cerebral vascular disease (CVD) 
free follow-up cohort, we excluded 215,900 individuals who 
had a diagnosis of stroke or MI during the baseline period. 
Thus, the sample for the prospective study of AMD and in-
cident stroke included 1,303,186 individuals aged 65 years 
or older and free of CVD at baseline. 
  We used the Medicare claim’s data of the follow-up period 
(January 1, 2002 to December 31, 2003) to identify the first 
occurrence of incident stroke among the baseline CVD-free 
cohort members. A person was identified as having incident 
stroke if he/she met any of the above stroke criteria during the 
follow-up period. Hemorrhagic stroke is defined as the occur-
rence of ICD-9 codes 430 - 432 or 342, and ischemic stroke is 
defined as the occurrence of ICD-9 codes (433 - 438). We 
only analyzed the first occurrence of stroke in this study. 
Table 1.  Definition of Key Variables and their Corresponding ICD-9 Codes 
 
Condition  ICD-9 Code   Definition 
Stroke [13]  342 
430 
431 
432 
433 
434 
435 
436 
437 
438 
V57 
Hemiplegia and hemiparesis 
Subarachnoid hemorrhage 
Intracerebral hemorrhage 
Other and unspecific intracranial hemorrhage 
Occlusion and stenosis of precerebral arteries 
Occlusion of cerebral arteries 
Transient cerebral ischemia 
Acute, but ill-defined cerebovascular disease 
Other ill-defined cerebrovascular disease 
Late effects of cerebrovascular disease 
Care involving use of rehabilitation procedures 
Neovascular AMD [16,35]  362.42-362.43 
362.52 
362.53 
Serous or hemorrhagic detachment of retinal pigment epithelium 
Exudative senile macular degeneration of retina 
Cystoid macular degeneration of retina 
Non-neovascular [16, 35]  362.5 
362.50 
362.51 
362.57 
Degeneration of macula and posterior pole 
Unspecified macular degeneration (senile) of retina 
Nonexudative senile macular degeneration of retina 
Drusen (degenerative) of retina 
Hypertension  401.0 - 401.9 
402.00 - 402.91 
403.00 - 403.91 
404.00-404.93 
Essential hypertension 
Hypertensive heart disease 
Hypertensive renal disease 
Hypertensive heart and renal disease  
Diabetes   250.00-250.93 
357.2 
362.01 
362.02 
366.41 
Diabetes 
Polyneuropathy in diabetes 
Background diabetic retinopathy 
Proliferative diabetic retinopathy 
Diabetic cataract 
MI  410.00 - 410.92  Acute myocardial infarction 
AMD: Age-related Macular Degeneration; MI: Myocardial Infarction. Is AMD Associated with Incident Stroke?  The Open Ophthalmology Journal, 2008, Volume 2    39 
Analysis Methods 
  The mean and standard deviation (SD) or proportion of 
demographic variables and co-morbidity were calculated. 
Logistic regression models were used to estimate the multi-
variable adjusted, as well as age group stratified, incident 
odds ratios and 95% confidence interval (CI) of stroke asso-
ciated with baseline AMD. All analyses were performed 
using SAS software v9.13 (The SAS Institute, Cary, NC). 
RESULTS 
  In the 5% random sample of Medicare Beneficiaries, we 
identified 1,519,086 individuals, aged 65 or older at baseline, 
as our potential study population. After excluding 215,900 
individuals who were identified as having history of stroke 
or MI during the two-year baseline period (January 1, 2000 
to December 31, 2001), we included 1,303,186 individuals 
as our cohort members for the prospective study of the rela-
tionship between baseline AMD and incident stroke. During 
the two-year follow-up period (January 1, 2002 to December 
31, 2003), we identified 89,501 individuals as having inci-
dent stroke, with a two-year cumulative incidence of 6.9%. 
Among them, 80,018 (89.4%) were classified as ischemic 
stroke, 7048 (7.9%) as hemorrhagic stroke, and 2,435 (2.7%) 
as having stroke diagnostic codes for both types of stroke. In 
this cohort, 10.6% individual had AMD at baseline. 19.7% 
of these persons had neovascular AMD and 80.3% had non-
neovascular AMD. The descriptive characteristics of the 
study population, stratified by baseline AMD type, are sum-
marized in Table 2. Briefly, in the cohort, the average age 
was 75 years (SD=7.7), with 60% women and 88% whites. 
Among persons without AMD (non-AMD group), the aver-
age age was 75 (SD=7.5) years, with 59% women and 87% 
whites, and the prevalence of hypertension and diabetes was 
61% and 23%, respectively. At the baseline, the AMD group 
was older with higher proportions of women and whites, and 
had higher prevalence of hypertension and diabetes than the 
non-AMD group (all p<0.01). As presented in Table 2, in the 
univariate analysis without adjusting for any potential con-
founders, the incidence of stroke, both ischemic and hemor-
rhagic forms, was higher among persons with AMD than 
among persons without AMD. Table 3 shows the age, race, 
gender, hypertension, and diabetes adjusted two-year cumu-
lative incidences (95% CI) of stroke according to baseline 
AMD status and age group. Consistently across all age 
strata, the incidence of stroke was higher among persons 
with baseline AMD for both neovascular and non-
neovascular AMD, and the incidence of stroke was the high-
est in persons with neovascular AMD and older age group. 
Table 4 presents the age, gender, race, hypertension, and 
diabetes adjusted two-year incident odds ratios and 95% CI 
of all stroke, ischemic stroke, and hemorrhagic stroke asso-
ciated with AMD, in the entire cohort and stratified by age 
group. Similar to the patterns observed in Table 3, persons 
with AMD were more likely to develop stroke when com-
pared with persons without AMD at baseline (referent 
group). For example, in the all-age group, persons with 
neovascular AMD at baseline had a 31% higher risk of de-
veloping stroke within two years than persons without AMD 
at baseline. When stratified by stroke types, persons with 
AMD at baseline, either neovascular or non-neovascular 
AMD, had approximately 15-30% higher risk of developing 
ischemic or hemorrhagic stroke within two years of follow-
up, and the association was not different by stroke types. 
Overall, the data on Table 4 are indicative of slightly higher 
risk of stroke associated with neovascular AMD than non-
neovascular AMD, and the AMD and stroke association was 
similar in magnitude for both types of stroke. 
  It should be noted that in the results presented in Table 4, 
we included all first incident stroke cases (n=89,501) for the 
Table 2.  Characteristics (Mean, SD, or Proportion) of Study Population by Baseline AMD Status 
 
   Non-AMD (N=1,165,348)  Neovascular AMD (N=27,193)   Non-neovascular AMD (N=110,645) 
Age (years)  75 (7.5)  80 (7.2)  80 (7.5) 
Female (%)  59  65  68 
White (%)  87  94  94 
Hypertension* 61  74  71 
Diabetes* 23  29  24 
Incident Stroke (%)  6.6  10.3  9.2 
*Diagnostic codes submitted during the 2-year baseline period. 
AMD: Age-related Macular Degeneration; SD: Standard Deviation. 
 
Table 3.  Multivariable Adjusted* 2-Year Incidence (%) and 95% CI of Stroke, Stratified by AMD and Age Group 
 
Age Group (Year) 
  All Age Group N=1,303,186 
65-69 (N=345,309)  70-74 (N=315,770)  75-79 (N=272,825)  > 80 (N=369,282) 
Non-AMD  6.35 (6.30, 6.40)  4.05 (3.98, 4.12)  5.29 (5.20, 5.37)  7.03 (6.92, 7.13)  9.26 (9.16, 9.37) 
Non-neovascular AMD  7.41 (7.27, 7.56)  4.25 (3.89, 4.64)  5.94 (5.62, 6.28)  8.12 (7.80, 8.45)  10.78 (10.52,11.04) 
Neovascular AMD  8.15 (7.85, 8.45)  5.77 (4.98, 6.68)  6.25 (5.61, 6.95)  8.44 (7.81, 9.11)  11.73 (11.21,12.28) 
*Adjusted for age within each age group, gender, race, hypertension, and diabetes. 
CI: Confidence Interval; AMD: Age-related Macular Degeneration. 40    The Open Ophthalmology Journal, 2008, Volume 2  Liao et al. 
analysis of all stroke. However, when stratified by stroke 
types, we only included solid ischemic stroke (n=80,018) 
and solid hemorrhagic stroke (n=7,048), by excluding 2,435 
stroke cases who had stroke diagnostic codes for both types 
of stroke in their first stroke claim forms. We performed 
additional sensitivity analysis by classifying these “mixed” 
cases either as ischemic or hemorrhagic stroke, and the pat-
tern of associations (data not shown) did not change mean-
ingfully from that presented in Table 4. 
DISCUSSION 
  Age-related macular degeneration is highly prevalent 
among elderly individuals in developed countries. An earlier 
study (1980) estimated that 6% of the US population aged 
65-74 years, and 20% of those older than 75 years, are af-
fected by AMD [14], which causes 54% of legal blindness in 
persons 65 years of age or older [14]. It was recently esti-
mated that 1.56 million US citizens 65 years of age and older 
are affected by neovascular AMD, and this number is esti-
mated to increase to almost 3 million by 2020 [15]. Data 
from one study suggested that the 5-year incidence of 
neovascular AMD, which has been reported to be responsi-
ble for 90% of severe vision loss associated with AMD, in 
Medicare Beneficiaries was 18.7 per 1000 [16]. 
  Several epidemiological studies have provided data con-
cerning risk factors associated with AMD. The most promi-
nent risk factors are older age, genetic factors [1-3], cigarette 
smoking [4, 5], and less consistently oxidative stress, long-
term exposure to light, low levels of antioxidants [6,7], and 
other nutritional factors [8], obesity [9, 10], and serum lipid 
levels [11, 12]. However, the pathological processes through 
which these factors may contribute to AMD remain poorly 
understood. Others have reported that women and whites are 
at higher risk of AMD [14, 16]. The associations between 
AMD and hypertension and diabetes mellitus have been 
found to be inconsistent [17-29]. 
  In a previous study using the same data as this study, we 
found that AMD was associated with older age, female gen-
der, and white race. Furthermore, AMD, especially neovas-
cular AMD, was cross-sectionally associated with the pres-
ence of hypertension, diabetes mellitus, and MI, independent 
of age, gender, and race[30]. In the prospective analysis, we 
reported that baseline AMD was significantly associated 
with the development of incident MI [30]. 
  In the current study, the results stratified by AMD-type 
and stroke-type, show that both neovascular AMD and non-
neovascular AMD are associated with incident ischemic and 
hemorrhagic stroke. However, neovascular AMD is a 
stronger predictor than non-neovascular AMD, and the AMD 
is a stronger predictor for ischemic than for hemorragic 
stroke. For example, compared to non-AMD group, baseline 
neovascular AMD was associated with a 31% increased risk 
of incident ischemic stroke, vs 18% for non-neovascular 
AMD. Similarly, baseline neovascular AMD was associated 
with a 26% increased risk of incident hemorrhagic stroke, vs 
22% for non-neovascular AMD. To our knowledge, this is 
the largest population-based study to demonstrate a signifi-
cant prospective association between AMD and stroke. The 
results from this study are similar to that reported by Wong 
and colleagues [31] in the population-based Arthrosclerosis 
Risk in Communities (ARIC) study - after adjusting for age, 
sex, ethnicity, and site, blood pressure, diabetes, cigarette
 
smoking, and use of antihypertensive medications, the pres-
ence
  of early-stage AMD was associated with a 85% in-
creased risk of incident stroke as compared to persons with-
out AMD. These data suggest that AMD and stroke may 
share some common antecedents. We speculate that the pres-
ence of AMD is a risk indicator of higher levels of various 
exposures not measured in the current study, e.g., cigarette 
Table 4.  Multivariable Adjusted* 2-Year Incident Odds Ratios and 95% CI of Stroke, Stratified by AMD-Type and Age Group 
 
Age Group 
  All Age Group 
65-69 70-74 75-79  > 80 
Combined Stroke (n=89,501) 
Non-AMD  1.00 1.00 1.00 1.00 1.00 
All AMD  1.21 (1.18, 1.23)  1.15 (1.06, 1.24)  1.16 (1.10, 1.22)  1.20 (1.15, 1.25)  1.20 (1.17, 1.24) 
 Non-neovascular AMD  1.18 (1.15, 1.21)  1.06 (0.96, 1.16)  1.14 (1.08, 1.22)  1.19 (1.13, 1.24)  1.18 (1.15, 1.22) 
 Neovascular AMD  1.31 (1.26, 1.36)  1.50 (1.28, 1.75)  1.22 (1.09, 1.36)  1.24 (1.14, 1.35)  1.30 (1.23, 1.37) 
Ischemic Stroke (n=80,018) 
All AMD  1.20 (1.18, 1.23)  1.14 (1.05, 1.24)  1.15 (1.09, 1.22)  1.21 (1.16, 1.26)  1.20 (1.16, 1.23) 
 Non-neovascular AMD  1.18 (1.15, 1.20)  1.05 (0.95, 1.16)  1.14 (1.07, 1.21)  1.20 (1.14, 1.26)  1.17 (1.14, 1.21) 
 Neovascular AMD  1.31 (1.26, 1.37)  1.49 (1.26, 1.75)  1.22 (1.08, 1.38)  1.25 (1.14, 1.37)  1.29 (1.22, 1.37) 
Hemorrhagic Stroke (n=7,048) 
All AMD  1.23 (1.15, 1.32)  1.26 (0.94, 1.63)  1.20 (0.99, 1.44)  1.17 (1.01, 1.35)  1.23 (1.13, 1.35) 
 Non-neovascular AMD  1.22 (1.14, 1.32)  1.19 (0.86, 1.60)  1.15 (0.93, 1.42)  1.17 (1.00, 1.37)  1.24 (1.12, 1.36) 
 Neovascular AMD  1.26 (1.10, 1.45)  1.53 (0.84, 2.54)  1.38 (0.92, 1.98)  1.16 (0.85, 1.55)  1.21 (1.00, 1.45) 
*Adjusted for age within each age group, gender, race, hypertension, and diabetes. Persons without AMD during the baseline period comprised the referent group. 
CI: Confidence Interval; AMD: Age-related Macular Degeneration. Is AMD Associated with Incident Stroke?  The Open Ophthalmology Journal, 2008, Volume 2    41 
smoking, inflammation [32] and subclinical artherosclerosis 
[22, 33]. Although not adjusted for these “not measured” 
confounding factors, these weak associations (all odds ratios 
less then 2.00) suggest that AMD is a “minor” predictor of 
incident stroke under an etiological model. However, a pub-
lic health perspective argues that estimates of the magnitude 
observed in this study would suggest that the population 
burden of stroke associated with AMD is still high due to 
high prevalence of AMD among elderly Americans. 
  Medicare claims data from Medicare beneficiaries have 
been used for various research projects. The enrollment rate 
in the Medicare system among the elderly American popula-
tion remains extremely high. For example, there are cur-
rently about 40 million Americans aged 65 years or older 
enrolled in Medicare, which accounts for approximately 98% 
of elderly Americans. Thus, medical claims data from these 
Medicare beneficiaries provide a very large sample size, 
which would be unmatchable by any other population-based 
studies. Additionally, Medicare data provide the greatest 
representative sample of the US population aged 65 years or 
older. 
  There are limitations of using Medicare claims data. 
First, the claims based data vary in terms of sensitivity and 
specificity for the diagnosis of chronic conditions. For ex-
ample, in a study comparing the Medicare claim-based ICD-
9 codes with hospital chart review, it was shown that the 
sensitivity and specificity for the claim-based diagnosis of 
hypertension were 0.61 and 0.95, respectively [34]. In the 
same study, the sensitivity and specificity for the claim-
based diagnosis were 0.75 and 0.99 for diabetes, 0.57 and 
0.96 for coronary heart diseases, and 0.35 and 0.99 for stroke 
[34]. In another similar study, the sensitivity and specificity 
were 0.69 and 0.83 for hypertension, 0.90 and 0.93 for dia-
betes, 0.58 and 0.93 for heart failure, and 0.68 and 0.95 for 
glaucoma [35]. Similarly, our classifications of AMD and 
incident stroke, the key predictor and outcome variables, 
were solely based on the claims diagnostic codes, without 
the ability to obtain results from medical charts pertaining to 
eye examinations, retinal photographs, cerebral CAT scan or 
MRI, or any other neurological tests. Therefore, we cannot 
confirm the diagnosis of these conditions in this study, nor 
can we provide direct assessment of the sensitivity and 
specificity of the major variables analyzed in this study. 
However, our findings would have been biased toward the 
null if the misclassification due to limited sensitivity, and to 
a less degree limited specificity, were non-differential, that 
is, there was no difference in misclassifying incident stroke 
due to AMD status. In addition, in this report, ICD-9 code 
362.53 was used in the algorithm to identify persons as 
neovascular AMD (to be consistent with the report by Lee 
and co-workers [36]). In practice, this code is used to code 
other non-AMD conditions also. We performed two addi-
tional sensitivity analyses by either classifying ICD-9 code 
362.53 as non-neovascular, or as non-AMD, and the pattern 
of association did not change meaningfully (data not shown). 
Second, because the data are claim based, we did not have 
the ability to ascertain the chronic conditions prior to the 
study period. Therefore, we can only analyze the chronic 
conditions within the study period and assume that the ab-
sence of a condition during the baseline period represents a 
negative history of such condition. For example, when we 
excluded persons with stroke at baseline period to derive a 
cohort of baseline stroke-free cohort, we may have misclas-
sified some individuals as “stroke-free” because we assumed 
they did not have a history of stroke prior to the year 2000. 
However, it is possible that some individuals in this cohort 
had a stroke prior to year 2000 but did not seek medical serv-
ices for their past stroke during the two-year baseline period. 
As a result, he/she would be classified as a stroke-free indi-
vidual at baseline. Thirdly, we cannot ascertain that a claim 
for stroke diagnosis during the follow-up period truly repre-
sents an incident stroke during that period. It is possible that 
the Medicare service was provided for a stroke that occurred 
prior to the follow-up or even before year 2000. Another 
major limitation of this study is the unavailability of estab-
lished stroke risk factors from the claims databases. For ex-
ample, data on cigarette smoking (both history and inten-
sity), obesity, physical activity, and alcohol consumption 
cannot be derived from the CMS database. Therefore, we 
cannot control for the potential confounding by these risk 
factors, nor can we assess the direct impact of such potential 
confounding on our findings. However, based on the popula-
tion based Atherosclerosis Risk in Communities (ARIC) 
study data [31], which reported a significant association be-
tween AMD and incident stroke after statistically controlling 
for smoking status and other lifestyle factors, it is not likely 
that the associations observed in our study can be fully at-
tributable to the lack of control of these lifestyle factors. 
  Despite the inherent limitations of using Medicare claims 
data as outlined above, the validity of these data is supported 
by the fact that our findings of AMD being associated with 
older age, female gender, white race, hypertension, and dia-
betes are consistent with the findings in several other studies 
using different populations and methods. Our prospective 
findings indicate that baseline AMD, especially neovascular 
AMD, is associated with higher risks of ischemic and hemor-
rhagic incident strokes, independent of baseline demographic 
factors and co-morbidity. These findings, if confirmed by 
other studies that control for smoking and other lifestyle co-
variables not measured in this study, are suggestive of the 
possibility of shared common antecedents between AMD 
and stroke. 
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